Information de reference pour ce titreAccession Number: | 00019053-201028070-00004.
|
Author: | Brown, Jack 1 2 3; Paladino, Joseph A. 1 4
|
Institution: | (1) State University of New York at Buffalo School of Pharmacy and Pharmaceutical Science, Buffalo, New York, USA (2) State University of New York at Buffalo School of Public Health, Buffalo, New York, USA (3) University of Rochester Medical Center, Department of Pharmacy, Rochester, New York, USA (4) CPL Associates, LLC, Amherst, New York, USA
|
Title: | Impact of Rapid Methicillin-Resistant Staphylococcus aureus Polymerase Chain Reaction Testing on Mortality and Cost Effectiveness in Hospitalized Patients with Bacteraemia: A Decision Model.[Article]
|
Source: | Pharmacoeconomics. 28(7):567-575, July 1, 2010.
|
Abstract: | Background: Patients hospitalized with Staphylococcus aureus bacteraemia have an unacceptably high mortality rate. Literature available to date has shown that timely selection of the most appropriate antibacterial may reduce mortality. One tool that may help with this selection is a polymerase chain reaction (PCR) assay that distinguishes methicillin (meticillin)-resistant S. aureus (MRSA) from methicillin-susceptible S. aureus (MSSA) in less than 1 hour. To date, no information is available evaluating the impact of this PCR technique on clinical or economic outcomes.
Objective: To evaluate the effect of a rapid PCR assay on mortality and economics compared with traditional empiric therapy, using a literature-derived model.
Methods: A literature search for peer-reviewed European (EU) and US publications regarding treatment regimens, outcomes and costs was conducted. Information detailing the rates of infection, as well as the specificity and sensitivity of a rapid PCR assay (Xpert MRSA/SA Blood Culture PCR(TM)) were obtained from the peer-reviewed literature. Sensitivity analysis varied the prevalence rate of MRSA from 5% to 80%, while threshold analysis was applied to the cost of the PCR test. Hospital and testing resource consumption were valued with direct medical costs, adjusted to year 2009 values. Adjusted life-years were determined using US and WHO life tables. The cost-effectiveness ratio was defined as the cost per life-year saved. Incremental cost-effectiveness ratios (ICERs) were calculated to determine the additional cost necessary to produce additional effectiveness. All analyses were performed using TreeAge Software (2008).
Results: The mean mortality rates were 23% for patients receiving empiric vancomycin subsequently switched to semi-synthetic penicillin (SSP) for MSSA, 36% for patients receiving empiric vancomycin treatment for MRSA, 59% for patients receiving empiric SSP subsequently switched to vancomycin for MRSA and 12% for patients receiving empiric SSP for MSSA. Furthermore, with an MRSA prevalence of 30%, the numbers of patients needed to test in order to save one life were 14 and 16 compared with empiric vancomycin and SSP, respectively. The absolute mortality difference for MRSA prevalence rates of 80% and 5% favoured the PCR testing group at 2% and 10%, respectively, compared with empiric vancomycin and 18% and 1%, respectively, compared with empiric SSP. In the EU, the cost-effectiveness ratios for empiric vancomycin- and SSP-treated patients were [Euro sign]695 and [Euro sign]687 per life-year saved, respectively, compared with [Euro sign]636 per life-year saved for rapid PCR testing. In the US, the cost-effectiveness ratio was $US898 per life-year saved for empiric vancomycin and $US820 per life-year saved for rapid PCR testing. ICERs demonstrated dominance of the PCR test in all instances. Threshold analysis revealed that PCR testing would be less costly overall, even at greatly inflated assay prices.
Conclusion: Rapid PCR testing for MRSA appears to have the potential to reduce mortality rates while being less costly than empiric therapy in the EU and US, across a wide range of MRSA prevalence rates and PCR test costs.
Copyright 2010 Adis Data Information BV
|
Author Keywords: | cost-effectiveness; diagnostic-assays; methicillin-resistant-staphylococcus-aureus-infections, treatment; staphylococcal-infections, treatment.
|
References: | 1. Grundmann H, Aires-de-Sousa M, Boyce J, et al. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006 Sep 2; 368 (9538): 874-85
2. Institute for Healthcare Improvement. Reduce methicillin-resistant staphylococcus aureus (MRSA) infection [online]. Available from URL: http://www.ihi.org/IHI/Programs/...- ouverture dans une nouvelle fenêtre [Accessed 2010 Mar 16]
3. Crum NF, Lee RU, Thornton SA, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 2006 Nov; 119 (11): 943-51
4. Romero-Vivas J, Rubio M, Fernandez C, et al. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995 Dec; 21 (6): 1417-23
5. Lodise TP Jr, McKinnon PS, Levine DP, et al. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007 Oct; 51 (10): 3731-3
6. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003 Jan 1; 36 (1): 53-9
7. Hay JW. Evaluation and review of pharmacoeconomic models. Expert Opin Pharmacother 2004 Sep; 5 (9): 1867-80
8. US Bureau of Labor Statistics. Office of Publications and Special Studies [online]. Available from URL: http://www.bls.gov/opub/- ouverture dans une nouvelle fenêtre [Accessed 2010 Mar 18]
9. Data on file, Cepheid Inc., 2009
10. Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus. Ann Int Med 1941; 68: 851-75
11. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000 Feb; 30 (2): 368-73
12. Gentry CA, Rodvold KA, Novak RM, et al. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy 1997 Sep-Oct; 17 (5): 990-7
13. Wolk DM, Struelens MJ, Pancholi P, et al. Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol 2009 Mar; 47 (3): 823-6
14. Welch KE, Goff DA, Fish DN, et al. A multi-center economic analysis of bacteremia caused by methicillin-resistant Staphylococcus aureus [abstract no. 1865]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA)
15. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999 Jun; 20 (6): 408-11
16. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005 Jun; 52 (2): 113-22
17. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005 Feb; 26 (2): 166-74
18. Chaix C, Durand-Zaleski I, Alberti C, et al. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999 Nov 10; 282 (18): 1745-51
19. Greiner W, Rasch A, Kohler D, et al. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin Microbiol Infect 2007 Mar; 13 (3): 264-8
20. Goff DA. Optimizing antimicrobial stewardship and therapy using a rapid MRSA/SA blood test [abstract]. European Congress of Clinical Microbiology and Infectious Diseases 2010 Apr 10-13; Vienna
|
Language: | English.
|
Document Type: | Original Research Articles.
|
Journal Subset: | Pharmacology.
|
ISSN: | 1170-7690
|
NLM Journal Code: | b1v, 9212404
|
DOI Number: | https://dx.doi.org/10.2165/11533...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|